Yet Another Bulletin Board

Welcome, Guest. Please Login or Register.
Nov 22nd, 2024, 6:35pm

Home Home Help Help Search Search Members Members Member Map Member Map Login Login Register Register
Clusterheadaches.com Message Board « Cafergot/ergotamine & serious drug interaction »


   Clusterheadaches.com Message Board
   New Message Board Archives
   Medications, Treatments, Therapies 2002
(Moderator: DJ)
   Cafergot/ergotamine & serious drug interaction
« Previous topic | Next topic »
Pages: 1  Reply Reply Notify of replies Notify of replies Send Topic Send Topic Print Print
   Author  Topic: Cafergot/ergotamine & serious drug interaction  (Read 325 times)
Bob_Johnson
New Board Hall of Famer
USA 
*****





   
Email

Gender: male
Posts: 1796
Cafergot/ergotamine & serious drug interaction
« on: Nov 15th, 2002, 10:54am »
Quote Quote Modify Modify

Cafergot Plus CYP 3A4 Inhibitor Linked With Fatal Ischemia
 
Nov. 14, 2002 — Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of Cafergot with potent CYP 3A4 inhibitors, including protease inhibitors and macrolide antibiotics, the U.S. Food and Drug Administration (FDA) reported today. Cafergot is indicated for the treatment of migraine and vascular headache.  
 
CYP 3A4 inhibition elevates the serum levels of Cafergot (a combination of ergotamine tartrate and caffeine), which increases the risk of vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Because of the increased risk of serious vasospastic adverse events, concomitant use of these medications is contraindicated.
 
In a letter to healthcare providers about its drug, Novartis Pharmaceuticals pointed out changes to the prescibing information for Cafergot, including a new boxed warning regarding the threat of serious and/or life-threatening peripheral ischemia.
 
Healthcare professionals should report all serious adverse events suspected to be associated with use of Cafergot to Novartis at (800) 448-5938 or to the FDA's MedWatch Reporting System by phone at 1-800-FDA-1088, by fax 1-800-FDA-0178, by mail using the Form 3500 at MedWatch, HF-2, 5600 Fishers Lane, Rockville, MD 20857; or via the internet at https://www.accessdata.fda.gov/scripts/medwatch.
 
The full revised prescribing information is available on the FDA Web site in PDF format at http://www.fda.gov/medwatch/SAFETY/2002/cafergot_PI.pdf.
========================================
 
"Ischemia" is a serious restriction in blood flow which can lead to organ damage or death.
 
Protease inhibitors are, for example, ritonavir.
Macrolide antibiotics, e.g., troleandomycin, clarithromycin, erythromycin.
 
The revised patient information available at the FDA site, above, also notes INDERAL can cause these problems.
-----------------------------------------
 
Bottom line: if you are using any of these medications, call this report to your physician's attention and stop using them in  the combinations noted here until cleared by your doc.
 
IP Logged

Bob Johnson
Karla
CH.com Alumnus
New Board Hall of Famer
USA 
*****




One of Many and Never Alone - Join OUCH

  Karlak_1313  
Email

Gender: female
Posts: 3090
Re: Cafergot/ergotamine & serious drug interaction
« Reply #1 on: Nov 15th, 2002, 11:10am »
Quote Quote Modify Modify

Thank you for sharing the news with us.  This is very important to some users.
IP Logged

Karla
suffer chronic ch
ch.com groupie since 1999
Proud Mom of Chris USMC Semper Fi
Pages: 1  Reply Reply Notify of replies Notify of replies Send Topic Send Topic Print Print

« Previous topic | Next topic »


Clusterheadaches.com Message Board » Powered by YaBB 1 Gold - SP 1.3.1!
YaBB © 2000-2003. All Rights Reserved.


©1998-2010 Web Vision Enterprises All rights reserved. All information on this site is protected by international copyright laws. You may not re-distribute any information from this site without written permission from Web Vision Enterprises and the webmaster of this site. Violators will be prosecuted.
You may view our privacy policy and financial disclosure statement here

test rss